ROXANE LABORATORIES, INC. ANNOUNCES THE LAUNCH OF QUETIAPINE FUMARATE TABLETS

COLUMBUS, OH – March 27, 2012 – Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25mg, 50mg, 100mg, 200mg, 300mg, and 400mg  by the U.S. Food and Drug Administration. The product is available in 25mg bottles of 100 and 1000 tablets, 50mg bottles of 100 and 1000 tablets, 300mg bottles of 60 tablets and 100mg, 200mg, 400mg bottles of 100 tablets for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories’ Quetiapine Fumarate Tablets are AB rated to SEROQUEL® (quetiapine fumarate) tablets. Annual sales of SEROQUEL® are approximately $4.6 Billion¹.

Full prescribing information for Quetiapine Fumarate Tablets is available on the Roxane Laboratories website at www.RLI-TouchPoint.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

For more information, please visit http://www.Roxane.com.

About Boehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For more information, please visit http://us.boehringer-ingelheim.com.